drugset / Trial / NCT00690677

Phase II Trial of LBH589 in Refractory Colorectal Cancer

NCT00690677

Phase 2 Completed 29 enrolled Swedish Medical Center Novartis · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the effects of the study drug, LBH589, on patients with metastatic colorectal cancer that has continued to grow despite previous treatment.

Timeline

Start
2008-06
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Panobinostat Small molecule 30 mg Oral

Indications